Meda, Vivus deal

Vivus will divest all assets related to erectile dysfunction (ED) drug Muse alprostadil to partner Meda for $22 million up front in cash, plus a potential $1.5 million milestone. The assets include U.S. and foreign patents, existing inventory and the manufacturing facility located in Lakewood, N.J. Vivus employees involved with Muse, including the field sales force, will join Meda. Meda already has European rights to Muse. Vivus reported $18.2 million in worldwide revenues for Muse in 2009. Muse is a pellet placed in the urinary opening to self-dispense the vasoactive drug alprostadil. The transaction is expected to close on or before Nov. 15. ...